Please explain to me how my assumptions are superficial and suspicious? I post here regularly and provide input like everyone else. I prefer to be balanced and raise questions about timing, effectiveness, etc. like others do. My assumptions are rational based on the time it takes to enroll patients, get the number needed to release interim data and scrub that data for release. CYDY has delays all the time, so waiting longer would not be a surprise and wouldn’t effect the stock price.

Define “soon” for the drug demonstrating effectiveness? Consider that the data from each patient has to be scrubbed prior to being shared or released. So other potential patients may not hear about the results until maybe a few weeks after the first CRC draw (5 weeks if I remember correctly) is taken? Lets call that 8 weeks, adding 3 weeks for the scrub and sharing. So 8 weeks from the first patient word gets out that leronlimab has reduced CTCs and others start to enter the trial. Those new patients still have to be screened before starting, and that takes time. So it’s not unreasonable to say that it may take up to 6 months from now to get interim results because of the time it takes to enroll patients and get the word out.